Search Results
Your search for ,HIS matches 4536 pages
Showing 3701 - 3750Utah Center for Genetic Discovery to Integrate Genome Data Into Patient Care
The USTAR Center for Genetic Discovery is partnering with California-based Omicia, Inc, to make analyzing a patient’s genome as routine as performing a blood test. The center, codirected by Mark Yandell, PhD, and Gabor Marth, DSc, was launched this month with $6 million from the University of Utah...
Informed Consent: Not Just About Blood Tests and Procedures Anymore
On February 24, the Institute of Medicine National Cancer Policy Forum convened a workshop, “Contemporary Issues in Human Subjects Protection in Cancer Research,” in Washington, DC. In his introduction to the workshop, Steven Piantadosi, MD, PhD, Director, Samuel Oschin Cancer Institute,...
Raj Mantena, RPh, Makes $1 Million Donation to Conquer Cancer Foundation to Help Build the Future of Cancer Care
It is a challenge faced time and time again by oncologists: how to achieve the best possible outcomes for patients while simultaneously controlling costs, providing care that is both high quality and high value. Raj Mantena, RPh, the first individual to donate $1 million dollars to the Conquer...
Cancer Research Funding Still Tight—and Getting Tighter
Margaret Foti, PhD, MD (hc), CEO of the American Association for Cancer Research (AACR), welcomed about 150 congressional staffers to a March briefing in Washington, DC, with a plea for increased federal funding. “Extraordinary progress is being made in cancer research today, as evidenced by the...
Individualized Care Key to Cancer Pain Management at Sidney Kimmel Comprehensive Cancer Center
Learning about the particulars of each cancer patient’s pain and treating each case uniquely is the key to keeping pain manageable. That is the goal of the Duffey Pain and Palliative Care Program at The Sidney Kimmel Comprehensive Cancer Center in Baltimore. The team consists of physicians, nurse...
Targeting Cancer Stem Cells in Breast Cancer: A Potential Clinical Strategy
Preclinical models have suggested that cancer stem cells play a role in tumor recurrence and metastasis following adjuvant therapy, and Max S. Wicha, MD, and his research team are deciphering the mechanisms by which this might happen. A true understanding of cancer stem cells will have important...
Prostatectomy vs Radiotherapy: A Study for Cautious Interpretation
Men with newly diagnosed localized prostate cancer face a decision between prostatectomy and radiotherapy, treatments deemed similarly effective but with well-established trade-offs in terms of treatment-related morbidity. Numerous clinical trials and other prospective studies, from both academic...
AACR Awards Webster Cavenee, PhD, Award for Leadership, Achievements
Webster K. Cavenee, PhD, was honored with the eighth annual American Association for Cancer Research (AACR) Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research at the AACR Annual Meeting held recently in San Diego. Dr. Cavenee is Director of the Ludwig Institute for ...
Bladder Cancer Patient With Rare Genetic Mutations Shows Exceptional Response to Everolimus/Pazopanib Combination
A patient with advanced bladder cancer experienced a complete response for 14 months to the drug combination everolimus (Afinitor) and pazopanib (Votrient) in a phase I trial, and genomic profiling of his tumor revealed two alterations that may have caused this exceptional response, according to a...
Bringing the Humanistic Approach to Palliative Care: From Diagnosis and Throughout Disease Course
For much of her career in oncology, Teresa A. Gilewski, MD, has sought to bridge the science of medicine with the humanistic aspect of care. She has created the Art of Medicine lecture series at Memorial Sloan Kettering Cancer Center in New York, where she is a medical oncologist on the Breast...
Conquering Colorectal Cancer With Sanjay Goel, MD, the 2010 Advanced Clinical Research Award in Colorectal Cancer Recipient
Colorectal cancer is the third most common cancer diagnosed in both men and women in the United States, and about 1 in 20 individuals will develop colorectal cancer in their lifetime. The good news is that improvements in screening, earlier detection, and treatments are all leading to improved...
Expert Point of View: William Cliby, MD
When asked to comment on the study presented by Lin et al at the Annual Meeting on Women’s Cancer, William Cliby, MD, Chair, Division of Surgery, The Mayo Clinic, Rochester, Minnesota, said, “This study is important because of its size and the utilization of the National Cancer Data Base—the...
SIDEBAR: Should You Treat Smoldering Multiple Myeloma?
A recent article in The New England Journal of Medicine has provoked conversation about the management of smoldering multiple myeloma.1 At the recent National Comprehensive Cancer Network (NCCN) Annual Conference, Kenneth C. Anderson, MD, of Dana-Farber Cancer Institute, Boston, shared his thoughts ...
Case Studies: Collaborative Practice in Action
The panel presented two case studies—one on high-dose methotrexate toxicity and one on 5-FU toxicity—as a platform for discussion of considerations, challenges, and interconnected roles of oncologists, nurse practitioners, physician assistants, and clinical pharmacists in safely managing patients...
Collaborative Exchange: Indications and Dosing
Indications and Dosing of Methotrexate and 5-FU Dr. Campen: The interesting thing about methotrexate is that it has been used for such a long time. You would think there would be a specific dose that would be considered “high dose,” but high dose is actually quite variable. [Dosage] depends on the...
Breaking Bad News Badly Can Add to Upset
When the prognosis is poor, breaking the bad news badly can exacerbate the distress experienced by cancer patients and their families. A lack of sensitivity to patient and family emotions and not being attuned to how individual patients would prefer to be informed about their prognoses can result...
ASCO’s Visionary Founders
On April 9, 1964, seven physicians—Jane Cooke Wright, MD, FASCO; Arnoldus Goudsmit, MD, PhD; Fred J. Ansfield, MD, FASCO; Harry F. Bisel, MD, FASCO; Herman H. Freckman, MD, FASCO; Robert W. Talley, MD, FASCO; and William Wilson, MD, FASCO—met for lunch at the Edgewater Beach Hotel in Chicago. They...
Duquesne University Awarded $1.4 Million NIH Grant
Duquesne University’s newly established biomedical engineering initiative has received a $1.4 million, 5-year grant from the National Institutes of Health’s National Cancer Institute to detect, capture and analyze circulating melanoma cells. John Viator, MD, Biomedical Engineering Program Director...
Schwartz Center Rounds® Programs Foster Clinical Teamwork and Enhance Patient Care
In the fall of 1994, 40-year-old Kenneth B. Schwartz, a health-care lawyer, was diagnosed with lung cancer. Radiation and chemotherapy failed to stop progression of the disease, and 10 months later he died. During his treatment, Mr. Schwartz wrote about the ordeal of coming to grips with the...
Irving Bone Marrow Transplant Unit Opens at NewYork-Presbyterian/Columbia
New York-Presbyterian/Columbia University Medical Center has opened the Irving Bone Marrow Transplant Unit, a state-of-the-art facility for comprehensive bone marrow transplant (BMT) care. The new unit features 18 inpatient rooms, a high-tech nurses station for individual patient monitoring, and a...
Bert Howard O’Neil, MD, Joins Indiana University Simon Cancer Center
Bert Howard O’Neil, MD, has been named the inaugural Joseph W. and Jackie J. Cusick Professor of Oncology and a Professor of Medicine at the Indiana University (IU) School of Medicine, in Indianapolis. He is also the Phase I Director and Director of the Gastrointestinal Cancer Research Program at...
American Association for Cancer Research Inaugurates New Leadership at 2014 Annual Meeting
The American Association for Cancer Research welcomed Carlos L. Arteaga, MD, as President of the Organization for 2014–2015. Dr. Arteaga was inaugurated during the AACR’s Annual Meeting. Dr. Arteaga is Professor of Medicine and Cancer Biology at Vanderbilt University School of Medicine, where he...
Genetic Testing Beneficial in Melanoma Treatment, UPCI Study Shows
Genetic screening of cancer can help doctors customize treatments so that patients with melanoma have the best chance of beating it, according to the results of a clinical trial by researchers at the University of Pittsburgh Cancer Institute. The trial, funded by the National Institutes of...
Creating a Comprehensive Catalog of Cancer Genes to Improve Patient Outcomes
In January, Eric S. Lander, PhD, Director of the Broad Institute of MIT and Harvard in Cambridge, Massachusetts, and his colleagues published the results from their landmark study,1 which explored the feasibility of creating a comprehensive catalog of cancer genes. The researchers collected and...
Forward Progress in Myelodysplastic Syndromes Is Largely in Genetics
Most recent advances in the management of myelodysplastic syndrome (MDS) are in the area of genetics, according to Steven Gore, MD, of Yale University School of Medicine, New Haven. “New genomics research is leading to a better understanding of MDS heterogeneity and disease biology, and may...
Setting a ‘Moon Shots’ Goal to Drastically Reduce Cancer Mortality Over the Next Decade
In 2012, just 1 year after taking the reins as President of The University of Texas MD Anderson Cancer Center, Ronald A. DePinho, MD, announced his plans to launch the Moon Shots Program, the most ambitious endeavor undertaken by the cancer center to dramatically accelerate the pace of reducing...
James P. Allison, PhD, Receives 2014 Canada Gairdner International Award
The Gairdner Foundation of Canada has named James P. Allison, PhD, for one of its 2014 Canada Gairdner International Awards. Dr. Allison is Chair and Professor of Immunology at The University of Texas MD Anderson Cancer Center in Houston. The honor, announced recently by the Gairdner Foundation,...
AACR Honors Douglas Hanahan, PhD, With AACR Lifetime Achievement in Cancer Research Award
Douglas Hanahan, PhD, Director of the Swiss Institute for Experimental Cancer Research at the Swiss Federal Institute of Technology, in Lausanne, Switzerland, was recently honored with the 11th annual American Association for Cancer Research (AACR) Lifetime Achievement in Cancer Research. The award ...
Conquer Cancer Foundation and Strike 3 Foundation Work Together to Conquer Pediatric Cancers
Envision a world where a diagnosis of pediatric cancer is met with the same reaction as a diagnosis of the common cold. In this idyllic world, the word “cancer” no longer carries with it the same traumatic response or stigma that it does today. This hopeful vision is what drives Craig Breslow in...
American Society of Clinical Oncology Honors Researchers, Patient Advocates, and Leaders of the Global Oncology Community
Leaders in cancer care will be recognized as part of the American Society of Clinical Oncology Special Awards Program at the 2014 ASCO Annual Meeting. The Special Awards recognize the dedication and significant contributions of researchers, patient advocates, and leaders of the global oncology...
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Announces Faculty Appointments, Grants
Noah M. Hahn, MD, has been selected as Associate Professor of Oncology and Urology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore. Before joining Johns Hopkins, Dr. Hahn was the Director of the Genitourinary Medical Oncology Program at Indiana University. He is an...
Michael S. Gordon, MD, Named Medical Director for Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare
Michael S. Gordon, MD, has been named the new Medical Director for the Virginia G. Piper Cancer Center Clinical Trials program at Scottsdale Healthcare in Phoenix. Dr. Gordon will oversee the center’s phase I clinical trials program. Virginia G. Piper Cancer Center Clinical Trials at Scottsdale...
Neoadjuvant Chemotherapy Without Routine Radiotherapy Shows Promise in Patients With Locally Advanced Rectal Cancer
In a pilot study reported in the Journal of Clinical Oncology, Deborah Schrag, MD, MPH, and colleagues from Memorial Sloan Kettering Cancer Center, New York, assessed outcomes with neoadjuvant FOLFOX (fluorouracil, leucovorin, oxaliplatin)/bevacizumab (Avastin) with selective use of...
Demanding More From Clinical Trials
“The function of the formal controlled clinical trial is to separate the relative handful of discoveries that prove to be true advances in therapy from a legion of false leads and unverifiable clinical impressions, and to delineate in a scientific way the extent of and the limitations that attend...
Challenges in Creating and Promoting Clinical Practice Guidelines
With regard to clinical practice guidelines, clinicians want an authoritative resource that will clearly and concisely instruct them in most clinical scenarios. Guideline developers want to give them this, “but producing guidelines is not as straightforward as it might seem,” according to David...
The Affordable Care Act: NCCN Panelists Rate It ‘Average’
Oncologists and third-party payers are already experiencing changes as a result of the Affordable Care Act, which earned an “average” rating by a panel of providers, payers, and patients assembled at the 19th Annual Conference of the National Comprehensive Cancer Network (NCCN) in Hollywood,...
Andrew D. Zelenetz, MD, PhD, on Treating the Elderly Lymphoma Patient With Elevated Bilirubin
At the 19th Annual Conference of the National Comprehensive Cancer Network (NCCN), lymphoma expert and NCCN Panel Chair on Lymphoma, Andrew D. Zelenetz, MD, PhD, fielded questions from oncologists. The ASCO Post was there to capture his recommendations for a common clinical scenario—treating the...
Blood Test Can Identify Prostate Cancer Patients Who Are Not Likely to Respond to Enzalutamide
A simple blood test may be able to identify men with castration-resistant prostate cancer who will not respond to enzalutamide (Xtandi). The presence of the splice variant androgen receptor (AR) V7 in circulating tumor cells identified men who were unlikely to respond to enzalutamide and whose...
Reflecting on the Past Year and Looking Ahead to the Next
On assuming the Presidency of ASCO a year ago, I recognized that one of our greatest challenges as a professional society is helping the American public understand the value of cancer research, especially now, when scientific advances are accelerating but resources are contracting. This is partly...
About the Artist
Keith Witmer received his Bachelor’s degree in Fine Arts from Otis/Parsons School of Design. He subsequently launched his career in advertising and publication with a commanding presence, initially using pen and ink and scratchboard mediums. Working with clients such as FedEx, Apple Computer,...
About the Writer
Ronald Piana is an independent writer and reporter with more than 15 years of experience in oncology communications and publishing. In addition to the profiles published in this special anniversary issue of The ASCO Post, Ron has written more than 100 articles, interviews, and profiles for leading...
Ernest Louis Mazzaferri, Sr, MD: September 27, 1936–May 14, 2013
Ernest Louis Mazzaferri, Sr, MD, MACP, of Henderson, Nevada, passed away peacefully at home on May 14, 2013 after a short illness, surrounded by his family. He was born September 27, 1936 in Cleveland, Ohio. Dr. Mazzaferri spent most of his medical career at The Ohio State University, serving as...
Janet L. Rowley, MD: April 5, 1925–December 17, 2013
Dr. Janet L. Rowley’s groundbreaking research in the translocation of genetic material bucked scientific convention and heralded a new understanding that cancer is indeed a genetic disease. Her research was largely responsible for the discoveries that led to the development of the targeted cancer...
Geoffrey P. Herzig, MD: December 6, 1941–December 20, 2013
Many of the advances that have bettered mankind are attributed to those who were driven by a primary passion. Geoffrey P. Herzig, MD, lived the better part of his life with a primary passion: conducting research to increase the cure rate of leukemia and lymphoma patients. His friend and colleague,...
Donald L. Morton, MD: September 12, 1934–January 10, 2014
Donald L. Morton, MD, transformed the management of melanoma and breast cancer by introducing the sentinel node biopsy, giving surgeons an accurate roadmap for treatment, and sparing generations of cancer patients from the morbidity associated with unnecessary surgery. Throughout his distinguished...
Peter Jacobs, MD, PhD: 1934–2013
Peter Jacobs, MD, PhD, regarded as the father of hematology in his native country of South Africa, began each day at 3 AM in the gym. During his workout, Dr. Jacobs would routinely call the nursing staff for updates on patients in his ward. Before sunup, Dr. Jacobs was on his way to the hospital....
ASCO’s Visionary Founders
On April 9, 1964, seven physicians—Jane Cooke Wright, MD, FASCO; Arnoldus Goudsmit, MD, PhD; Fred J. Ansfield, MD, FASCO; Harry F. Bisel, MD, FASCO; Herman H. Freckman, MD, FASCO; Robert W. Talley, MD, FASCO; and William Wilson, MD, FASCO—met for lunch at the Edgewater Beach Hotel in Chicago. They...
David A. Karnofsky: The Man Behind the Karnofsky Memorial Award and Lecture
David A. Karnofsky, MD, dedicated himself to the pursuit of scientific excellence and the investigation of more effective therapies for cancer for nearly 30 years, from the time he was a young resident at the Collis P. Huntington Memorial Hospital for Cancer Research of Harvard University, until...
Understanding the Relationship Between the Lab and the Clinic is Key to 2014 Karnofsky Memorial Award Honoree’s Success
The island nation of Curaçao is nestled in the southern Caribbean Sea off the Venezuelan coast. Curaçao was first settled by the Arawaks, an Amerindian people that inhabited the island for hundreds of years before the arrival of Europeans. Amid one wave of settlers from Portugal and Spain that...
Enthusiasm and Vision Guide the Head of FDA’s Oncology Office
In 2005, Richard Pazdur, MD, was named the FDA’s Director of the Office of Hematology and Oncology Products. By any measure, being arbiter of the nation’s oncology drug pipeline is a daunting prospect, but Dr. Pazdur sees it as an opportunity to encourage his talented staff to work for the greater ...
